Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA ...
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
UCB Canada Inc. is pleased to announce Health Canada has granted a Notice of Compliance (NOC) for PrBIMZELX® (bimekizumab injection) indicated for the treatment ...
AZoLifeSciences on MSN
Early disease detection through microbiome biomarkers and sequencing technologies
Microbiome diagnostics and AI are redefining early disease detection, emphasizing the gut's impact on health and the ...
Prevalence of Autism Spectrum Disorder (ASD) among children and youth aged 1 to 17 years, is about 2% (1 in 50) and is equivalent to about 150,000 cases in Canada in 2025 [1, 2]. Smith-Magenis ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...
EG110A is a non-replicating HSV-1 vector designed to selectively silence the signals of type C sensory neurons responsible ...
Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral ant ...
From eradicating smallpox to battling the COVID-19 pandemic, these vaccine pioneers have helped make colossal strides in ...
Analysis - What should have passed as a routine adjustment in Nigeria's tax code has instead unfolded as a daily drama of debit alerts and doubt, turning a fifty-naira stamp duty into a mirror ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback